Compare Abeona Therapeutics Inc (ABEO) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Kinross Gold Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Kinross Gold Corporation trades at $23.04 (market cap $28.53B). The key difference: Kinross Gold Corporation is far larger — about 76.4× Abeona Therapeutics Inc's market cap, and Kinross Gold Corporation pays a 0.61% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | KGC | |
|---|---|---|
Market Cap | $373.32M | $28.53B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $38.06 |
52-Week Low | $4.17 | $15.19 |
Enterprise Value | $228.22M | $27.08B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Kinross Gold (KGC) trades at $23.87, down 3.4% over 24 hours amid a bearish technical signal. The company demonstrates strong fundamentals with revenue growing from $3.5B in 2022 to $7.05B in 2025 and net income surging to $2.39B. Recent quarters show consistent earnings beats, with Q2 2026 results expected on July 29. Analyst consensus remains bullish with a $35.33 price target representing 48% upside potential.
KGC presents a compelling value opportunity with attractive valuation ratios (P/E 10.52, EV/EBITDA 5.46) and robust profitability (35.99% net margin). Key risks include gold price volatility and rising operational costs. The company's strong cash flow generation and growth projects support long-term upside, though technical indicators suggest near-term consolidation may continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
